Distribution was constant over time, although the sulfonylurea prescriptions as a combination treatment showed a negative trend, with DPP4i becoming the most prescribed from 2017 (Fig. 1 of the ESM).
← all excerpts
Impact of Second-Line Combination Treatment for Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study.
1
—
—